Personalis announced that the US Centers for Medicare & Medicaid Services will cover its NeXT Personal minimal residual disease (MRD) test for surveillance of stage II–III breast cancer in Medicare beneficiaries, with coverage for up to six years. The decision follows clinical data showing the assay detected recurrence months to years earlier than imaging. NeXT Personal is a tumor‑informed, whole‑genome sequencing LDT performed in Personalis’ CAP‑accredited CLIA lab. A study in Annals of Oncology reported detection of 100% of recurrent breast cancers in the trial and durable negative predictive value in patients who remained disease‑free. CMS coverage validates the clinical utility and economic argument for MRD surveillance in oncology and could accelerate adoption of tumor‑informed liquid biopsies in post‑treatment monitoring.